Sanofi-Aventis' Lovenox sNDA Granted Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi's low molecular weight heparin has an early June user fee date for a STEMI claim.
You may also be interested in...
Lovenox Clears FDA For STEMI After Priority Review
The low molecular weight heparin joins Plavix in the STEMI space.
Lovenox Clears FDA For STEMI After Priority Review
The low molecular weight heparin joins Plavix in the STEMI space.
GSK’S Arixtra “Approvable” For Acute Coronary Syndromes
Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.